


UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO. **FILING DATE** FIRST NAMED INVENTOR ATTORNEY DOCKET NO. LUDEVID HM11/0427 **EXAMINER** KRISTINA BIEKER BRADY ZAGHMOUT,O CLARK & ELBING 176 FEDERAL STREET **ART UNIT** PAPER NUMBER BOSTON MA 02110 04/27/00 DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



Applicant(s)

Ludevid et al.

Office Action Summary

Examiner

09/117,246

Ousama Zaghmout

Group Art Unit 1649



X Responsive to communication(s) filed on Jul 27, 1998	•
☐ This action is FINAL .	
☐ Since this application is in condition for allowance except for f in accordance with the practice under <i>Ex parte Quayle</i> , 1935	
A shortened statutory period for response to this action is set to is longer, from the mailing date of this communication. Failure to application to become abandoned. (35 U.S.C. § 133). Extension 37 CFR 1.136(a).	respond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	
☐ Claim(s)	is/are rejected.
Claim(s)	
	are subject to restriction or election requirement.
Application Papers See the attached Notice of Draftsperson's Patent Drawing The drawing(s) filed on is/are objecte The proposed drawing correction, filed on The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign priority under All Some* None of the CERTIFIED copies of received. received in Application No. (Series Code/Serial Number received in this national stage application from the Interval of the company is a content of the company is a content of the conten	d to by the Examiner. isapproveddisapproved. Inder 35 U.S.C. § 119(a)-(d). Ithe priority documents have been
*Certified copies not received:	
☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).	
Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper Notice of Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PTO-948 Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION ON THE FOLLOWING PAGES	

Serial Number: 09/117,246 Page 2

Art Unit: 1649

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
- I. Claims 1-5 are drawn to an oligonucleotide, a less than full length nucleotide sequence, classified in class 536, subclass 24.2 for example.
- II. Claims 6-23, 28-41 are drawn to a recombinant nucleotide sequence comprising a concatenation of nucleotide coding for a plant protein reserve, expression vector, a method of transformation, and resulting transgenic plants, classified in class 800, subclass 278 for example.
- III. Claims 24-27 are drawn to a protein, classified in class 530, subclass 300, for example.
- 2. The inventions are distinct, each from the other because of the following reasons:
- a. Each invention is drawn to a molecularly and a biochemically divergent products and processes not required by the other.
- b. Group I is drawn to a an oligonucleotide, a less than full length nucleotide sequence. Not related to the invention of group II which requires the use a full length

Serial Number: 09/117,246

Page 3

Art Unit: 1649

nucleotide sequence. Furthermore, the plant expression vector, method of transformation and resulting of transgenic plants of group II are not required by inventions of either group I or III.

Not related to group III which can be made by methods other than the use of the oligonucleotide of group I or the nucleotide sequence of group II, such as chemical synthesis.

As such, the invention of each group is independent and patentability distinct. Clearly, they are independent since you could practice one invention without practicing or infringing any of the others. Similarly, each is patentability distinct since they constitute different products which can each support its own patent.

As such, the invention in each one of these groups require separate search and it be burden on the Examiner to examine more than one invention in one application.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their divergent subject matter, classification, and fields of search, restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

Serial Number: 09/117,246 Page 4

Art Unit: 1649

amendment of inventorship must be accompanied by a diligently-filled petition under 37 CFR 1.148(b) and the fee required under 37 CFR 1.17(h).

Art Unit: 1649

Future Correspondence

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Ousama M-Faiz Zaghmout whose telephone number is (703) 308-9438. The Examiner can normally be reached Monday through Friday from 7:30 am to 5:00 pm (EST).

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, L. Smith, can be reached on (703) 308-3909. The fax phone number for the group is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application should be directed to THE MATRIX CUSTOMER SERVICE CENTER whose telephone number is (703) 308-0196.

Ousama M-Faiz Zaghmout Ph.D. July 5, 1999

LYNETTE R. F. SMITH SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

Page 5